Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › obeticholic acid

obeticholic acid

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of obeticholic acid

6 trials tracked of obeticholic acid.

6Trials tracked
0Phase 3 & 4
0Recruiting
0With published results
Phase distribution
Phase 2 5 Phase 1 1
  1. Phase 2 Phase 2 Study of Obeticholic Acid for Lipodystrophy Patients Completed
  2. Phase 2 Obeticholic Acid in Bile Acid Diarrhoea Completed
  3. Phase 2 The Farnesoid X Receptor (FXR) Ligand Obeticholic Acid in NASH Treatment Trial(FLINT) Completed
  4. Phase 2 Combination Obeticholic Acid (OCA) and Statins for Monitoring of Lipids (CONTROL) Completed
  5. Phase 2 Phase 2 Study on Effects of Obeticholic Acid (OCA) on Lipoprotein Metabolism in Participants With Primary Biliary Cirrhosis Completed
  6. Phase 1 Linerixibat and Obeticholic Acid Drug Interaction Study in Healthy Subjects Completed

Showing the 6 most-cited and recently-updated of 6 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Seladelpar 10 mg shows optimal risk-benefit profile for UDCA-refractory primary biliary cholangitis patients
Drug Pipeline Meta-analysis
Seladelpar 10 mg shows optimal risk-benefit profile for UDCA-refractory primary biliary cholangitis patients New data identifies promising treatments for primary biliary cholangitis
This network meta-analysis of 1,540 patients evaluates various therapies for primary biliary cholangitis (PBC) with inadequate response to U…
New research identifies specific medications that may improve liver health and relieve itching for patients with primary biliary cholangitis…
Frontiers Sep 13, 2026
Network meta-analysis finds pegozafermin, OCA, and resmetirom outperform placebo for MASLD fibrosis improvement
Gastroenterology Meta-analysis
Network meta-analysis finds pegozafermin, OCA, and resmetirom outperform placebo for MASLD fibrosis improvement New Liver Treatments Show Real Promise in Reversing Scarring
A systematic review and network meta-analysis of 10,119 adult patients with MASLD found pegozafermin, obeticholic acid (OCA), and resmetirom…
For the first time, doctors have clear evidence that new medications can help reverse the dangerous liver scarring caused by common fatty li…
Apr 10, 2026